Imaging the neural effects of cannabinoids: Current status and future opportunities for psychopharmacology

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2603-2614

  Bhattacharyya, S ^a   Crippa, J A ^b   Martin Santos, R ^c   Winton Brown, T ^a   Fusar Poli, P ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anxiety; Cannabidiol; Cannabis; Delta 9 tetrahydrocannabinol; Endocannabinoid; Functional magnetic resonance imaging; Psychosis

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DRONABINOL; G PROTEIN COUPLED RECEPTOR;

ANXIETY DISORDER; BRAIN BLOOD FLOW; BRAIN METABOLISM; CLINICAL TRIAL; DIFFUSION TENSOR IMAGING; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; EMOTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE ACTIVATION; GENE EXPRESSION; HUMAN; LEARNING; LOW DRUG DOSE; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; STIMULUS RESPONSE; TASK PERFORMANCE; TIME PERCEPTION; TRANQUILIZING ACTIVITY; TREATMENT DURATION;

ANXIETY DISORDERS; BRAIN; CANNABINOIDS; COGNITION; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING; MARIJUANA ABUSE; MODELS, NEUROLOGICAL; PSYCHOPHARMACOLOGY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 69249116618     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957465     Document Type: Review

References (169)

1. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58(4): 315-48.
2. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: The hash realities. Nat Rev Neurosci 2007; 8(11): 885-95.
3. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553-74.
4. Watson SJ, Benson JA, Jr., Joy JE. Marijuana and medicine: Assessing the science base: A summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000; 57(6): 547-52.
5. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 28 2007; 370(9584): 319-28.
6. World Drug Report UNODC. United Nations Office on Drugs and Crime [online]. http://www.unodc.org/documents/wdr/WDR_2008_eng_web.pdf Accessed on Jan 1, 2009.
7. Ashton H. Cannabis or health? Curr Opin Psych 2002; 15: 247-53.
8. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53(1): 90-4.
9. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 2008; 33(9): 2061-79.
10. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.
11. Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 1967; 25: 175-213.
12. Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. Science 1970; 169(945): 611-2.
13. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352(9140): 1611-6.
14. Tart CT. Marijuana intoxication common experiences. Nature 1970; 226(5247): 701-4.
15. Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA 1969; 210(2): 299-302.
16. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004; 29(8): 1558-72.
17. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 2002; 164(1): 61-70.
18. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology (Berl) 2006; 188(4): 425-44.
19. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001; 25(5): 757-65.
20. McDonald J, Schleifer L, Richards JB, de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003; 28(7): 1356-65.
21. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend 2006; 85(2): 114-22.
22. Ramaekers J, Kauert G, Theunissen E, Toennes S, Moeller M. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2008.
23. Ilan AB, Smith ME, Gevins A. Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl) 2004; 176(2): 214-22.
24. Pope HG, Jr., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 275(7): 521-7.
25. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10): 909-15.
26. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. Jama 2002; 287(9): 1123-31.
27. Pope HG, Jr. Cannabis, cognition, and residual confounding. JAMA 2002; 287(9): 1172-4.
28. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004; 23(3): 914-20.
29. Howlett AC. The cannabinoid receptors. Prostagland Lipid Mediat 2002; 68-69: 619-31.
30. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199-215
31. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284): 561-4.
32. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87(5): 1932-6.
33. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001; 356(1407): 381-408.
34. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: A regional and laminar analysis. Cereb Cortex 2007; 17(1): 175-91.
35. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005(168): 327-65.
36. Kreitzer AC. Neurotransmission: Emerging roles of endocannabinoids. Curr Biol 2005; 15(14): R549-51.
37. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2-3): 101-21.
38. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: An in vivo microdialysis study. Brain Res 2002; 948(1-2): 155-8.
39. Gardner EL. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav 2005; 81(2): 263-84.
40. Nagai H, Egashira N, Sano K, Ogata A, Mizuki, K, Iwasaki K, et al. Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 2006; 84(2): 330-6.
41. Pisanu A, Acquas E, Fenu S, Di Chiara G. Modulation of Delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors. Neuropharmacology 2006; 50(6): 661-70.
42. Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3): 271-80.
43. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973; 25(8): 664-5.
44. Izquierdo I, Orsingher OA, Berardi AC. Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 1973; 28(1): 95-102.
45. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21(3): 175-85.
46. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76(3): 245-50.
47. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990; 100(4): 558-9.
48. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29(2): 417-26.
49. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66(1): 95-105
50. Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20(5): 683-6.
51. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97(17): 9561-6.
52. Zuardi A, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2008.
53. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances. Chem Biodivers 2007; 4(8): 1678-92.
54. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150(5): 613-23.
55. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95(14): 8268-73.
56. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134(4): 845-52.
57. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006; 103(20): 7895-900.
58. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30(8): 1037-43
59. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152(7): 1092-101.
60. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2(8574): 1483-6.
61. Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, et al. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med 2006; 36(10): 1441-6.
62. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on 3HCP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103(1): 9-15.
63. Zavitsanou K, Garrick T, Huang XF. Selective antagonist 3HSR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(2): 355-60.
64. Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006; 172(4): 556-60.
65. Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008; 65(7): 772-84.
66. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10(8): 1665-9.
67. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2: 5.
68. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29(11): 2108-14.
69. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Bmj 2005; 330(7481): 11.
70. Linszen DH, Dingemans PM, Nugter MA, Van der Does AJ, Scholte WF, Lenior MA. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull 1997; 23(1): 119-30.
71. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006; 189: 137-43.
72. Isaac M, Isaac M, Holloway F. Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol 2005; 20(3): 207-10.
73. Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 2003; 54(4): 554-61.
74. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 30 2007; 151(1-2): 151-4.
75. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, et al. Delta-9-tetrahydrocannabinol modulates medial temporal and striatal function in humans: A neural basis for the effects of cannabis on learning and psychosis. Archives of General Psychiatry (In Press).
76. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57(6): 594-608.
77. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155(6): 761-7
78. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1): 13-23.
79. Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 1978; 57(3): 243-8.
80. Maitre L, Staehelin M, Bein HJ. Effect of an extract of cannabis and of some cannabinols on catecholamine metabolism in rat brain and heart. Agents Actions 1970; 1(3): 136-43.
81. Banerjee SP, Snyder SH, Mechoulam R. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 1975; 194(1): 74-81.
82. Hershkowitz M, Szechtman H. Pretreatment with delta 1-tetrahydrocannabinol and psychoactive drugs: Effects on uptake of biogenic amines and on behavior. Eur J Pharmacol 1979; 59(3-4): 267-76.
83. Poddar MK, Dewey WL. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 1980; 214(1): 63-7.
84. Sakurai-Yamashita Y, Kataoka Y, Fujiwara M, Mine K, Ueki S. Delta 9-tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol Biochem Behav 1989; 33(2): 397-400.
85. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990; 102(2): 156-62.
86. Chen JP, Paredes W, Lowinson JH, Gardner EL. Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study. Neurosci Lett 1991; 129(1): 136-80.
87. French ED. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997; 226(3): 159-62.
88. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276(5321): 2048-50.
89. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology (Berl) 2007; 195(2): 255-64.
90. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. Sep 2004; 74(1): 1-58.
91. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52(1): 139-53.
92. Allen P, Aleman A, McGuire PK. Inner speech models of auditory verbal hallucinations: Evidence from behavioural and neuroimaging studies. Int Rev Psychiatry 2007; 19(4): 407-15.
93. Solowij N, Michie PT. Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 2007; 32(1): 30-52.
94. Krystal JH, Perry EB, Jr., Gueorguieva R, Belger A, Madonick SH, Abi-Darghum A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62(9): 985-94.
95. Fletcher PC, Honey GD. Schizophrenia, ketamine and cannabis: Evidence of overlapping memory deficits. Trends Cogn Sci 2006; 10(4): 167-74.
96. Block RI, O'Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11(3): 491-6.
97. Tzilos GK, Cintron CB, Wood JB, Simpson NS, Young AD, Pope HG Jr, et al. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict 2005; 14(1): 64-72.
98. Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol 2007; 17(4): 289-97.
99. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005; 77(1): 23-30.
100. Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65(6): 694-701.
101. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry 2007; 190: 230-6.
102. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study. Schizophr Res 2008; 99(1-3): 1-6.
103. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Hulshoff Pol H, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165(4): 490-6.
104. Gruber SA, Yurgelun-Todd DA. Neuroimaging of marijuana smokers during inhibitory processing: A pilot investigation. Brain Res Cogn Brain Res 2005; 23(1): 107-18.
105. Delisi LE, Bertisch HC, Szulc KU, Majcher M, Brown K, Bappal A, et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduct J 2006; 3: 17.
106. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. Corpus callosum damage in heavy marijuana use: Preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008; 41(3): 1067-74.
107. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: A meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005; 162(12): 2233-45.
108. Kyriakopoulos M, Bargiotas T, Barker GJ, Frangou S. Diffusion tensor imaging in schizophrenia. Eur Psychiatry 2008; 23(4): 255-73.
109. Tunving K, Thulin SO, Risberg J, Warkentin S. Regional cerebral blood flow in long-term heavy cannabis use. Psychiatry Res 1986; 17(1): 15-21.
110. Lundqvist T, Jonsson S, Warkentin S. Frontal lobe dysfunction in long-term cannabis users. Neurotoxicol Teratol 2001; 23(5): 437-43.
111. Mathew RJ, Tant S, Burger C. Regional cerebral blood flow in marijuana smokers. Br J Addict 1986; 81(4): 567-71.
112. Sneider JT, Pope HG, Jr., Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Altered regional blood volume in chronic cannabis smokers. Exp Clin Psychopharmacol 2006; 14(4): 422-8.
113. Sneider JT, Pope HG, Jr., Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. Eur Neuropsychopharmacol 2008; 18(8): 612-9.
114. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72(1-2): 237-50.
115. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: A functional magnetic resonance imaging study. Psychopharmacology (Berl) 2004; 176(3-4): 239-47.
116. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: An fMRI study. Psychopharmacology (Berl) 2006; 185(3): 358-68.
117. Mechoulam R. Marihuana chemistry. Science 1970; 168(936): 1159-66.
118. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63(2): 139-49.
119. Mathew RJ, Wilson WH, Tant SR. Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand 1989; 79(2): 118-28.
120. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 1992; 12(5): 750-8.
121. Mathew RJ, Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci 1993; 52(8): 757-67.
122. Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR. Marijuana intoxication and brain activation in marijuana smokers. Life Sci 1997; 60(23): 2075-89.
123. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res 1998; 797(2): 183-9.
124. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 1999; 100(1): 67-75.
125. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 1996; 67(1): 29-38.
126. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Weithe KE. Depersonalization after marijuana smoking. Biol Psychiatry 1993; 33(6): 431-41.
127. Mathew RJ, Wilson WH, Turkington TG, Hawk TC, Coleman RE, DeGrado TR, et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res 2002; 116(3): 173-85.
128. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26(6): 802-16.
129. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, et al. Marijuana alters the human cerebellar clock. Neuroreport 11 2003; 14(8): 1145-51.
130. O'Leary DS, Block RI, Koeppel JA, Schultz SK, Magnotta VA, Ponto LB, et al. Effects of smoking marijuana on focal attention and brain blood flow. Hum Psychopharmacol 2007; 22(3): 135-48.
131. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biol Psychiatry 2008; 64(11): 966-73.
132. Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris JG, et al. Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet 2000; 97(1): 58-64.
133. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry 2002; 59(4): 347-54.
134. Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A, et al. An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr Res 2001; 52(1-2): 47-55.
135. Kaladjian A, Jeanningros R, Azorin JM, Grimault S, Anton JL, Mazzola-Pomietto P. Blunted activation in right ventrolateral prefrontal cortex during motor response inhibition in schizophrenia. Schizophr Res 2007; 97(1-3): 184-93.
136. Lamers CT, Bechara A, Rizzo M, Ramaekers JG. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 2006; 20(2): 302-11.
137. Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull 2007; 133(5): 833-58.
138. Wagner AD, Schacter DL, Rotte M, Koutstaal W, Maril A, Dale AM, et al. Building memories: Remembering and forgetting of verbal experiences as predicted by brain activity. Science 1998; 281(5380): 1188-91.
139. Buckner RL, Wheeler ME. The cognitive neuroscience of remembering. Nat Rev Neurosci. Sep 2001; 2(9): 624-34.
140. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 2006; 9(12): 1526-33.
141. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology 2009; 34(3): 759-66.
142. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008; 28(10): 2313-9.
143. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81(2): 331-42.
144. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 2006; 5(5): 411-24.
145. Scatton B, Sanger DJ. Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11(3-4): 243-56.
146. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161(6): 975-84.
147. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009; 34(1): 187-203.
148. Zuardi AW, Karniol IG. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 1983; 16(2): 141-6.
149. Musty RE, Conti LH, Mechoulam R. Anxiolytic properties of cannabidiol. In: Harvey DJ, eds. Marihuana '84. Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited; 1984: 713-9.
150. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990; 253(3): 1002-9.
151. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 1994; 25(1): 161-4.
152. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7: 82-8.
153. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981; 37(10): 1090-2.
154. Ferrari MC, Busatto GF, McGuire PK, Crippa JA. Structural magnetic resonance imaging in anxiety disorders: An update of research findings. Rev Bras Psiquiatr 2008; 30(3): 251-64.
155. Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R. Cannabis-associated psychosis with hypomanic features. Lancet 1982; 2(8312): 1364-6.
156. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991; 104(2): 260-4.
157. Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 2004; 75(5): 633-8.
158. Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512(2-3): 199-205.
159. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006; 31(4): 795-803.
160. Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 2007; 97(1-3): 109-17.
161. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192(4): 306-7.
162. Yasuno F, Brown AK, Zoghabi SS, Krushinski JH, Chernet E, Tauscher J, et al. The PET radioligand 11CMePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology 2008; 33(2): 259-69.
163. Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry 2008; 42(5): 357-68.
164. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 2008; 198(4): 587-603.
165. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002; 2002(129): RE5.
166. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005; 19(1-2): 96-107.
167. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008; 14(23): 2326-36.
168. Fowler CJ. "The tools of the trade"--an overview of the pharmacology of the endocannabinoid system. Curr Pharm Des 2008; 14(23): 2254-65.
169. Viso A, Cisneros JA, Ortega-Gutierrez S. The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr Top Med Chem 2008; 8(3): 231-46.